-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, H9uYTXCOAzBYLfYQNkUa+UXwodW7svycDx222VT/8aKm6E3M3tbfJ7SSeRAE1+9+ qQoX1efWX9qFUGln+C/B1g== 0000950123-05-010802.txt : 20050907 0000950123-05-010802.hdr.sgml : 20050907 20050907145207 ACCESSION NUMBER: 0000950123-05-010802 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20050907 DATE AS OF CHANGE: 20050907 GROUP MEMBERS: NOVARTIS AG GROUP MEMBERS: NOVARTIS PHARMA AG SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IDENIX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001093649 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 450478605 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79969 FILM NUMBER: 051072564 BUSINESS ADDRESS: STREET 1: 60 HAMPSHIRE STREET STREET 2: . CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: (617) 250-3100 MAIL ADDRESS: STREET 1: 60 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: NOVIRIO PHARMACEUTICALS LTD DATE OF NAME CHANGE: 19990820 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Novartis Bioventures Ltd CENTRAL INDEX KEY: 0001297709 IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: C/O NOVARTIS INTERNATIONAL AG STREET 2: WSJ-200.220 CITY: CH-4002 BASEL STATE: V8 ZIP: 0000000000 BUSINESS PHONE: 41-61-324-6210 MAIL ADDRESS: STREET 1: C/O NOVARTIS INTERNATIONAL AG STREET 2: WSJ-200.220 CITY: CH-4002 BASEL STATE: V8 ZIP: 0000000000 SC 13D/A 1 y12462a1sc13dza.txt AMENDMENT #1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Idenix Pharmaceuticals, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock - -------------------------------------------------------------------------------- (Title of Class of Securities) 45166R 20 4 - -------------------------------------------------------------------------------- (CUSIP Number) Robert E. Pelzer, Esq. Morton A. Pierce, Esq. Novartis Pharma AG Dewey Ballantine LLP Lichtstrasse 35 1301 Avenue of the Americas CH-4002, Basel Switzerland New York, New York 10019 41-61-324-1111 (212) 259-8000 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) - -------------------------------------------------------------------------------- September 2, 2005 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box |_|. Note: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. The information required on this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Exchange Act") or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes). - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (entities only)* Novartis AG - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_| (b) |_| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* AF - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |_| - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Switzerland - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF 0 SHARES ------------------------------------------------------------ BENEFICIALLY 8 SHARED VOTING POWER OWNED BY EACH 27,356,739 REPORTING ------------------------------------------------------------ PERSON 9 SOLE DISPOSITIVE POWER WITH 0 ------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 27,356,739 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 27,356,739 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* |_| - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 56.8% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS Page 2 of 12 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (entities only)* Novartis Pharma AG - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_| (b) |_| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |_| - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Switzerland - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF 0 SHARES ------------------------------------------------------------ BENEFICIALLY 8 SHARED VOTING POWER OWNED BY EACH 27,356,739 REPORTING ------------------------------------------------------------ PERSON 9 SOLE DISPOSITIVE POWER WITH 0 ------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 27,356,739 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 27,356,739 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* |_| - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 56.8% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS Page 3 of 12 - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON (entities only)* Novartis BioVentures Ltd. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |_| (b) |_| - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |_| - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Bermuda - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF 0 SHARES ------------------------------------------------------------ BENEFICIALLY 8 SHARED VOTING POWER OWNED BY EACH 0 REPORTING ------------------------------------------------------------ PERSON 9 SOLE DISPOSITIVE POWER WITH 0 ------------------------------------------------------------ 10 SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* |_| - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.00% - -------------------------------------------------------------------------------- 14 TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS Page 4 of 12 Item 1. Security and Issuer This Amendment No. 1 to Schedule 13D (this "Amendment") amends the initial statement on Schedule 13D (the "Original Schedule 13D") filed with the Securities and Exchange Commission on July 27, 2004 relating to Common Stock (the "Common Stock"), par value $0.001 per share of Idenix Pharmaceuticals, Inc., a Delaware corporation (the "Company"). The address of the Company's principal executive offices is 60 Hampshire Street, Cambridge, Massachusetts 02139. Except as otherwise described herein, the information contained in the Original Schedule 13D remains in effect. Capitalized terms used but not defined in this Amendment shall have the respective meanings set forth with respect thereto in the Original Schedule 13D. Item 2. Identity and Background No change except as described below. (a) - (c) and (f) The name, business address, present principal occupation or employment and citizenship of the executive officers and members of the Board of Directors of each of the Reporting Persons is set forth on Schedule I hereto and is incorporated herein by reference. (d) and (e) Neither the Reporting Persons nor, to the best knowledge of each of them, any of the persons listed on Schedule I hereto with respect to each such Reporting Person during the last five years, (i) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration No change except as described below. On September 2, 2005 Novartis Pharma acquired from Novartis Bioventures 1,187,093 shares of Common Stock for $20.18 per share or an aggregate of $23,955,537. The source of funds for this acquisition was Novartis Pharma's working capital. Item 4. Purpose of Transaction No change except as described below. Stock Purchase Rights The 1,187,093 shares of Common Stock acquired from Bioventures will not be counted as shares held by Novartis Pharma for purposes of determining Novartis Pharma's percentage ownership in connection with its stock purchase rights pursuant to the Stockholders Agreement. Page 5 of 12 The responses set forth in Item 3 and Item 6 of this Statement are incorporated by reference in response to Item 4 of this Statement. Item 5. Interest in Securities of the Issuer No change except as described below. (a) and (b) Novartis is the beneficial owner of 27,356,739 shares of Common Stock representing 56.8% of the outstanding shares of Common Stock, all of which shares are owned directly by Novartis Pharma. Novartis has shared power to vote or direct the vote and shared power to dispose or to direct the disposition of all shares of Common Stock beneficially owned by it. Novartis Pharma is the record and beneficial owner of 27,356,739 shares of Common Stock, representing 56.8% of the outstanding shares of Common Stock. Novartis Pharma has shared power to vote or direct the vote and shared power to dispose or to direct the disposition of all shares of Common Stock beneficially owned by it. To the best knowledge of each of the Reporting Persons, none of the persons listed on Schedule I hereto with respect to such Reporting Person is the beneficial owner of any shares of Common Stock. (c) Except for the transactions described in Item 3 neither the Reporting Persons nor, to the best knowledge of each of the Reporting Persons, any of the persons listed on Schedule I has engaged in any transaction in the Common Stock in the past 60 days. (e) Novartis Bioventures ceased to be the beneficial owner of any of the Company's shares on September 2, 2005. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer No change. Item 7. Material to be Filed as Exhibits No change. Page 6 of 12 Signatures After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: September 2, 2005 NOVARTIS AG By: /s/ George Miller ---------------------------------- Name: George Miller Title: Authorized Signatory By: /s/ Peter Rupprecht ---------------------------------- Name: Peter Rupprecht Title: Authorized Signatory NOVARTIS PHARMA AG By: /s/ Robert E. Pelzer ---------------------------------- Name: Robert E. Pelzer Title: General Counsel By: /s/ Joseph E. Mamie ---------------------------------- Name: Joseph E. Mamie Title: Head Operational Treasury NOVARTIS BIOVENTURES LTD. By: /s/ Emil Bock ---------------------------------- Name: Emil Bock Title: Member of the Board of Directors Page 7 of 12 SCHEDULE I DIRECTORS AND EXECUTIVE OFFICERS OF NOVARTIS, NOVARTIS PHARMA AND NOVARTIS BIOVENTURES Directors and Executive Officers of Novartis The name, address, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis are set forth below. Unless otherwise indicated below, each occupation set forth opposite an individual's name refers to employment with Novartis. - -------------------------------------------------------------------------------- Name, Function and Business Address Citizenship Principal Occupation - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Daniel Vasella Switzerland Chairman of the Board of Chairman of the Board of Directors, Directors, Chief Chief Executive Officer Executive Officer c/o Novartis AG Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Prof. Dr. Helmut Sihler Austria Retired Vice Chairman of the Board of Directors c/o Novartis AG Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Hans-Jorg Rudloff Germany Chairman of the Executive Vice Chairman of the Board Committee of Barclays c/o Novartis AG Capital Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Birgit Breuel Germany Consultant Director c/o Novartis AG Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Prof. Dr. Peter Burckhardt Switzerland Head of Medical Service Director at the University c/o Novartis AG Hospital of Lausanne Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Prof. Dr. Srikant Datar India Senior Associate Dean for Director Executive Education at c/o Novartis AG Harvard Business School Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Page 8 of 12 - -------------------------------------------------------------------------------- Name, Function and Business Address Citizenship Principal Occupation - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- William W. George USA Senior Lecturer at Director Harvard Business School c/o Novartis AG Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Alexandre F. Jetzer Switzerland Consultant Director c/o Novartis AG Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Pierre Landoldt Switzerland President of the Sandoz Director family foundation c/o Novartis AG Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Dr. Ulrich Lehner Germany President and Chief Director Executive Officer of c/o Novartis AG Henkel KGaA Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Dr. Wendelin Wiedeking Germany Chairman and Chief Director Executive Officer of c/o Novartis AG Porsche AG Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Prof. Dr. Rolf M. Zinkernagel Switzerland Professor and Director of Director the Institute of c/o Novartis AG Experimental Immunology Lichtstrasse 35 at the University of CH-4002 Basel, Switzerland Zurich - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Dr. Raymund Breu Switzerland Chief Financial Officer c/o Novartis AG Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Dr. Urs Barlocher Switzerland Head of Legal and General c/o Novartis AG Affairs Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Juergen Brokatzky-Geiger Germany Head of Human Resources c/o Novartis AG Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Page 9 of 12 - -------------------------------------------------------------------------------- Name, Function and Business Address Citizenship Principal Occupation - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Paul Choffat Switzerland Head of Novartis Consumer c/o Novartis AG Health Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Thomas Ebeling Germany Head of Novartis Pharma c/o Novartis AG Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Prof. Marc C. Fishman, Md. USA Head of Pharmaceuticals c/o Novartis AG Research Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- Directors and Executive Officers of Novartis Pharma The name, address, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis Pharma are set forth below. Unless otherwise indicated below, each occupation set forth opposite an individual's name refers to employment with Novartis Pharma. - -------------------------------------------------------------------------------- Name, Function and Business Address Citizenship Principal Occupation - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Daniel Vasella Switzerland Chairman of the Board of Chairman of the Board of Directors Directors and Chief Chief Executive Officer Executive Officer of c/o Novartis AG Novartis AG Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Dr. Raymund Breu Switzerland Member of the Board of Director Directors c/o Novartis AG Lichstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Thomas Ebeling Germany Member of the Board of Director Directors, Head of Head of Management Management c/o Novartis AG Lichtstrasse 35 CH-4002 Basel, Switzerland - -------------------------------------------------------------------------------- Page 10 of 12 Directors and Executive Officers of Novartis BioVentures The name, address, citizenship and present principal occupation or employment of each of the directors and executive officers of Novartis BioVentures are set forth below. Unless otherwise indicated below, each occupation set forth opposite an individual's name refers to employment with Novartis BioVentures. - -------------------------------------------------------------------------------- Name, Function and Business Address Citizenship Principal Occupation - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Dr. Francois L'Eplattenier Switzerland Chairman Chairman c/o Novartis International AG Building WSJ-200 CH-4002, Basel, Switzerland. - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Timothy Faries Bermuda Director Director Appleby Spurling Hunter "Canon's Court" 22 Victoria Street Hamilton, Bermuda HM 12 - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Michael Jones Director and Secretary Appleby Spurling Hunter "Canon's Court" 22 Victoria Street Hamilton, Bermuda HM 12 - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- Emil Bock Germany Deputy Chairman Director General Manager c/o Novartis International Pharmaceutical Ltd. Hurst Holme 12 Trott Road Hamilton HM AA Bermuda - -------------------------------------------------------------------------------- Page 11 of 12 EX-99.1 2 y12462a1exv99w1.txt JOINT FILING AGREEMENT EXHIBIT 1 Joint Filing Agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of Idenix Pharmaceuticals, Inc., a Delaware corporation. Date: September 2, 2005 NOVARTIS AG By: /s/ George Miller ---------------------------------- Name: George Miller Title: Authorized Signatory By: /s/ Peter Rupprecht ---------------------------------- Name: Peter Rupprecht Title: Authorized Signatory NOVARTIS PHARMA AG By: /s/ Robert E. Pelzer ---------------------------------- Name: Robert E. Pelzer Title: General Counsel By: /s/ Joseph E. Mamie ---------------------------------- Name: Joseph E. Mamie Title: Head Operational Treasury NOVARTIS BIOVENTURES LTD. By: /s/ Emil Bock ---------------------------------- Name: Emil Bock Title: Member of the Board of Directors Page 12 of 12 -----END PRIVACY-ENHANCED MESSAGE-----